pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,294 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1062Endpoints800BioPharma Dive308BioSpace233Fierce Biotech221onclive165raps86globenewswire health
therapy area
allOncology6262Rare Disease1515Cardiology1173Hematology1088Immunology1056Vaccines960Pulmonology
  • BioCryst to shut internal drug discovery and close Alabama research site
    BioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…
    Endpoints · 1mo agoNegative↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 1mo agoRegulatoryNeutral↗ source
← prev
page 56 of 92
next →
73
fda recalls52
fda medwatch46
fda press29
926
Psychiatry & CNS754
Ophthalmology453
Pain419
Endocrinology & Metabolism399
Infectious Disease380
  • FDA’s top gene-therapy regulator Vijay Kumar steps down amid leadership shake-up
    Vijay Kumar, the acting director of the FDA office that reviews cell and gene therapies, has announced he will leave his position. In an email to staff, Kumar said he reflected on his tenure and de…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • AstraZeneca to Pay $34 Million Settlement Over Texas Medicaid Kickback Allegations
    AstraZeneca has agreed to a $34 million settlement with the Texas attorney general over allegations that it provided improper incentives to boost prescriptions covered by Texas Medicaid. The state…
    STAT · 1mo agoRegulatoryNegative↗ source
  • J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth Potential
    John Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical com…
    Endpoints · 1mo agoNeutral↗ source
  • Over 200 biopharma investors urge EU governments to strengthen Europe's life-science sector
    More than 200 biopharma investors and companies have signed an open letter addressed to EU member states, calling for action to improve Europe's life‑science sector. The signatories argue that Eur…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • California hospital lawsuits reveal forced McKinsey ties and surprise ER chain profits
    Unredacted comments from recent California hospital lawsuits show that hospital executives admitted to a "forced" partnership with consulting firm McKinsey, raising questions about the influence of…
    STAT · 1mo agoRegulatoryNegative↗ source
  • La Ceiba Foods recalls Salvadoran and Mexican cottage cheese over possible Listeria contamination
    La Ceiba Foods Latin Market Inc. announced on June 26, 2026 that it is recalling its Requesón Salvadoreño (Salvadoran cottage cheese) and Requesón Mexicano (Mexican cottage cheese) products sold un…
    fda recalls · 2mo agoRegulatoryNegative↗ source
  • Precision strategies help de-risk rare disease therapy launches
    Commercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…
    Fierce Biotech · 2mo agoNeutral↗ source
  • Endpoints News celebrates ten years of bootstrapped growth and a 50/50 founder partnership
    John Carroll and Arsalan Arif launched Endpoints News a decade ago with no seed funding or investors, describing themselves as completely broke. They built the news service from scratch, relying on…
    Endpoints · 2mo agoPositive↗ source
  • STAT readers split on spelling of "health care" as industry leans toward single word
    STAT recently asked its audience whether to write the term as two words or one. Roughly 60% of respondents favored one spelling over the other. The discussion highlights a subtle but growing trend…
    STAT · 2mo agoNeutral↗ source
  • STAT invites reader debate on blue zones and open-access publishing fees
    Torie Bosch, editor of STAT’s First Opinion platform, has published an opinion piece encouraging readers to submit letters responding to recent essays. The article explains that STAT will publish…
    STAT · 2mo agoNeutral↗ source
  • Weekly roundup highlights LGBTQ+ leadership in biopharma and reports of a Novo Nordisk hack
    The latest Endpoints Weekly newsletter was published on June 20, 2026, coinciding with the summer solstice in the northern hemisphere. The issue spotlights the growing visibility of LGBTQ+ leaders…
    Endpoints · 2mo agoNeutral↗ source
  • Daraxonrasib doubles median survival in pancreatic cancer trial, FDA grants early access
    An international study presented at the American Society of Clinical Oncology meeting in Chicago showed that patients with pancreatic cancer who received daraxonrasib lived an average of 13.2 month…
    STAT · 2mo agoPositive readoutPositive↗ source
  • US launches trade probe into Germany's plan to lower drug prices
    US Department of Commerce announced on June 19, 2026 that it has opened a Section 301 trade investigation targeting Germany’s drug pricing system. The probe follows Germany’s ongoing review of its…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • Tennessee pharmacies sell high-strength ivermectin under anti-vaccine doctor's direction
    Tennessee pharmacies have begun offering high-strength formulations of the antiparasitic drug ivermectin. The sales are being led by a physician known for anti-vaccine views, who has publicly said…
    STAT · 2mo agoNegative↗ source
  • Rural U.S. faces growing maternity care deserts despite falling fertility rates
    Pregnant women in many rural parts of the United States often must travel two hours or more to reach a hospital that can deliver a baby, putting them at risk if labor starts early or complications…
    STAT · 2mo agoNegative↗ source
  • Federal grant delays threaten disability research and services
    Grants from the National Institute on Disability, Independent Living, and Rehabilitation Research have been postponed by several months, leaving researchers uncertain about funding. The delays are…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Protego Biopharma appoints Jae Kim as chief medical officer
    Protego Biopharma announced the addition of Jae Kim to its executive team as chief medical officer. Kim comes to Protego after serving as chief medical officer at both Septerna and Design Therapeu…
    STAT · 2mo agoNeutral↗ source
  • CMS recalculates 2026 Medicare Advantage star ratings, increasing program volatility and affecting $16 billion in bonuses
    Federal officials have issued a new memo that recalculates the quality ratings for 2026 Medicare Advantage plans. The change follows another lawsuit from insurers that contest lower star ratings,…
    STAT · 2mo agoRegulatoryNegative↗ source
  • FDA advisory panel backs Moderna seasonal mRNA flu vaccine after earlier controversy
    A Food and Drug Administration advisory committee unanimously endorsed Moderna’s seasonal mRNA flu vaccine on Thursday, after the product became the focus of controversy earlier this year when a se…
    STAT · 2mo agoRegulatoryPositive↗ source
  • Eli Lilly stops 340B discounts for hospitals that did not submit required claims data
    Eli Lilly has begun withdrawing the federally mandated 340B price discounts from a handful of hospitals that have failed to provide the comprehensive claims data the company requires. The move fol…
    STAT · 2mo agoRegulatoryNegative↗ source
  • FDA lifts opposition to Huntington’s disease gene therapy, clearing path for development
    The Readout Loud podcast this week highlighted a regulatory shift for a gene therapy aimed at Huntington’s disease. The Food and Drug Administration reversed its earlier opposition, removing a key…
    STAT · 2mo agoRegulatoryPositive↗ source
  • Eli Lilly stops 340B discounts for dozens of hospitals that did not submit claims data
    Eli Lilly has begun removing the federally mandated 340B price discounts for a few dozen hospitals that have not provided the required claims data. The company said the step follows a warning it is…
    STAT · 2mo agoRegulatoryNegative↗ source
  • FDA vaccine advisors unanimously support Moderna's flu shot
    Every member of a vaccine advisory panel for the FDA voted in favor of Moderna’s flu vaccine, after the product faced roadblocks from previous agency leadership. The Vaccines and Related Biological…
    Endpoints · 2mo ago↗ source